Pharmacokinetics and safety of twice-daily atazanavir 300 mg and raltegravir 400 mg in healthy individuals

Antiviral Therapy

Volumn 15, Issue 8, 2010, Pages 1107-1114

  Zhu, Li ^a   Butterton, Joan ^b   Persson, Anna ^a   Stonier, Michele ^a   Comisar, Wendy ^b   Panebianco, Deborah ^b   Breidinger, Sheila ^b   Zhang, Jenny ^a   Bertz, Richard ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; RALTEGRAVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONFUSION; CONTROLLED STUDY; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HEART VENTRICLE EXTRASYSTOLE; HUMAN; HUMAN EXPERIMENT; HYPERBILIRUBINEMIA; JAUNDICE; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; PR INTERVAL; PRIORITY JOURNAL; QRS COMPLEX; QT PROLONGATION; SIDE EFFECT; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; FEMALE; HEART; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PYRIDINES; PYRROLIDINONES; TIME FACTORS; YOUNG ADULT;

EID: 78650987917     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1673     Document Type: Article

References (27)

1. Reyataz (atazanavir). US prescribing information 2009. Bristol-Myers Squibb, Princeton, NJ, USA.
2. Malan DR, Krantz E, David N, Wirtz V, Hammond J, McGrath D. Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients. J Acquir Immune Defic Syndr 2008; 47:161-167.
3. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008; 372:646-655.
4. Cahn PE, Gatell JM, Squires K, et al. Atazanavir - a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: results from two randomized clinical trials. J Int Assoc Physicians AIDS Care (Chic Ill) 2004; 3:92-98.
5. Isentress (raltegravir). US prescribing information 2009. Merck & Co., Inc., Whitehouse Station, NJ, USA.
6. Isentress (raltegravir). Summary of product characteristics 2009. Merck Sharp & Dohme, Limited, Hertfordshire, UK.
7. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. (Updated 1 December 2009. Accessed 4 December 2009.) Available from http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf
8. Carr A. Treatment strategies for HIV lipodystrophy. Curr Opin HIV AIDS 2007; 2:332-338.
9. Karras A, Lafaurie M, Furco A, et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis 2003;36:1070-1073.
10. Zimmermann AE, Pizzoferrato T, Bedford J, Morris A, Hoffman R, Braden G. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis 2006; 42:283-290.
11. Cazanave C, Dupon M, Lavignolle-Aurillac V, et al. Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. AIDS 2008; 22:395-402.
12. Foisy MM, Yakiwchuk EM, Hughes CA. Induction effects of ritonavir: implications for drug interactions. Ann Pharmacother 2008; 42:1048-1059.
13. Shibuyama S, Gevorkyan A, Yoo U, Tim S, Dzhangiryan K, Scott JD. Understanding and avoiding antiretroviral adverse events. Curr Pharm Des 2006; 12:1075-1090.
14. Grinsztejn B, Nguyen BY, Katlama C, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a Phase II randomised controlled trial. Lancet 2007; 369:1261-1269.
15. Zhu L, Mahnke L, Persson A, et al. Pharmacokinetics, safety and tolerability of atazanavir 200, 300, and 400 mg in healthy subjects. 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Annual Infectious Diseases Society of America Meeting. 25-28 October 2008, Washington, DC, USA.
16. Zhang D, Chando TJ, Everett DW, Patten CJ, Dehal SS, Humphreys WG. In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos 2005;33:1729-1739.
17. Kassahun K, McIntosh I, Cui D, et al. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos 2007; 35:1657-1663.
18. Iwamoto M, Wenning LA, Mistry GC, et al. Atazanavir modestly increases plasma levels of raltegravir in healthy subjects. Clin Infect Dis 2008; 47:137-140.
19. Iwamoto M, Kost JT, Mistry GC, et al. Raltegravir thorough QT/QTc study: a single supratherapeutic dose of raltegravir does not prolong the QTcF interval. J Clin Pharmacol 2008; 48:726-733.
20. Orrick JJ, Steinhart CR. Atazanavir. Ann Pharmacother 2004; 38:1664-1674.
21. Merschman SA, Vallano PT, Wenning LA, Matuszewski BK, Woolf EJ. Determination of the HIV integrase inhibitor, MK-0518 (raltegravir), in human plasma using 96-well liquid-liquid extraction and HPLC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 857:15-24.
22. Schuster A, Burzawa S, Jemal M, Loizillon E, Couerbe P, Whigan D. Quantitative determination of the HIV protease inhibitor atazanavir (BMS-232632) in human plasma by liquid chromatography-tandem mass spectrometry following automated solid-phase extraction. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 788:377-386.
23. US Food and Drug Administration. Guidance for industry: drug interaction studies - study design, data analysis, and implications for dosing and labeling. Silver Spring, MD: US Food and Drug Administration 2006.
24. Dickinson L, Khoo S, Back D. Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons. Curr Opin HIV AIDS 2008; 3:296-305.
25. Laine L. Acid secretion in human immunodeficiency virus infection. Gastroenterology 1993; 105:298-299.
26. Lake-Bakaar G, Elsakr M, Hagag N, et al. Changes in parietal cell structure and function in HIV disease. Dig Dis Sci 1996; 41:1398-1408.
27. Welage LS, Carver PL, Revankar S, Pierson C, Kauffman CA. Alterations in gastric acidity in patients infected with human immunodeficiency virus. Clin Infect Dis 1995; 21:1431-1438.